Previous 10 |
Thinly traded Principia Biopharma ( PRNB +1.1% ) is up, albeit on turnover of only 5K shares, following its announcement of positive results from an open-label Phase 2 clinical trial evaluating its lead candidate, Orphan Drug-tagged PRN1008, in pemphigus patients. The data were present...
-- Reached primary endpoint of Control of Disease Activity at four weeks in 54 percent of patients on low dose corticosteroids -- -- Median Anti-DSG antibodies reduced by up to 65 percent with 12 weeks of treatment -- -- Complete Response rate of 25 percent with 12 weeks of treat...
Thinly traded Principia Biopharma ( PRNB +3.4% ) is up on below-average volume on the heels of Phase 1 data on multiple sclerosis candidate PRN2246, a Bruton's tyrosine kinase (BTK) inhibitor that crosses the blood-brain barrier. The results were presented at ACTRIMS in Dallas, TX. Mor...
-- Orally administered PRN2246 achieved full BTK occupancy in peripheral blood -- -- PRN2246 exhibited blood-brain barrier permeability and CNS exposure -- -- Sanofi to lead Phase 2 development for people with Multiple Sclerosis -- SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE ...
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced tha...
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced tha...
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the...
News, Short Squeeze, Breakout and More Instantly...
Principia Biopharma Inc. Company Name:
PRNB Stock Symbol:
NASDAQ Market:
Principia Biopharma Inc. Website:
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral inve...
NEW YORK, NY / ACCESSWIRE / September 19, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Maxim Integrated Products, Inc. (NASDAQ: MXIM...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to e...